MOBI NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Mobia Medical, Inc. Common Stock · Healthcare · Medical Devices

Open interactive chart View report data Download investor PDF
Latest close 10.85 USD
-10.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is - below the Trend Line and sits at 13.0% of its 52-week range. The latest completed week returned -10.7%, after a -25.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 23 out of 100
Latest Close 10.85 USD 24 Jul 2026
1W Return -10.7% latest completed week
4W Return -25.8% short-term follow-through
12W Return - quarterly tape
Trend Breadth 0.0% 0 of 12 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -10.7% Latest completed week; four-week move -25.8%. Indicator stack 0/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 52/100 41 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is - below the Trend Line and sits at 13.0% of its 52-week range. The latest completed week returned -10.7%, after a -25.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0412-week average 0.04

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.04Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -25.8% over four weeks, - over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-10.7%
4W-25.8%
12W-
26W-
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality48/100Profitability and accounting quality. Underlying universe rank 53; rank 1 is best.
Momentum50/100Medium-term price momentum. Underlying universe rank 51; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
11.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-12.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
80.6%
Gross profit retained from each unit of revenue.
Operating margin
-144.7%
Operating profit retained from revenue.
Free-cash-flow margin
-141.5%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
104.8%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-17.9%
Net share repurchases relative to market value.
Shareholder yield
-17.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 41 relevant articles.

7 positive · 34 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-29.0%Distance below the 52-week high.
13-week volatility7.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher5 of 116 weeks finished lower.
Best week+15.8%Week of 19 Jun.
Worst week-10.7%Week of 24 Jul.
Latest week-10.7%Week of 24 Jul.

Shape of recent returns

Strong gains2
Modest gains3
Flat weeks0
Modest losses3
Sharp losses3
Recent vol7.4%13-week weekly-return volatility.
Base vol7.4%52-week weekly-return volatility.
Up/down split5/6Count of positive and negative weeks in the 52-week window.
Average skew5.9% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape26/100

Trend, activity pressure, participation, and risk combine to a 26/100 tape read.

 Indicator analysis5/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.04; 2 reversal markers Factors49/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 90; Small Cap Core rank 54 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 41 relevant articles.

Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202610.85 USD-10.7%-12.67 USD0.00-319.0KOff
17 Jul 202612.15 USD-0.3%-12.83 USD0.00-590.2KOff
10 Jul 202612.19 USD-10.7%-12.90 USD0.00-620.4KOff
3 Jul 202613.65 USD-6.7%-12.98 USD0.00-597.5KOff
26 Jun 202614.63 USD2.7%-12.89 USD0.00-549.5KOff
19 Jun 202614.25 USD15.8%-12.65 USD0.00-1.8MOff
12 Jun 202612.31 USD-2.5%-12.38 USD0.00-714.6KOff
5 Jun 202612.62 USD-3.7%-12.39 USD0.00-1.7MOff
29 May 202613.10 USD4.0%-12.34 USD0.00-328.0KOff
22 May 202612.60 USD5.9%-12.08 USD--328.5KOff
15 May 202611.90 USD1.3%-11.82 USD--823.3KOff
8 May 202611.75 USD--11.75 USD--2.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.